Home » Newsletters » BioWorld Asia

BioWorld Asia

Sep. 27, 2000

View Archived Issues

Peptide Alliance With Baxter Puts End To Merger Talks With Cantab

Scotia Suffers Setback As Foscan Deemed Not Approvable By FDA

XTL Raises $44M In London IPO; Company Value Grows To $230M

Genmab Seeks EUR240M In Dual Neuer Markt, Copenhagen IPO

Other News To Note

Stem Cells From Brain Can Form Muscle Cells, Italian Study Shows

Pantheco Reports Progress With AntiSense Antibiotics

Meristem Completes Phase I Of Plant Engineered-Derived Drug

Oxford Glyco Seeks Added Nasdaq Listing For U.S. Deals

EU Committee Shoots Down Italian Concerns Over GM Food

NIH Funds Study Of NicOx Drugs For Cancer Indications

Syn X Pharma Expands Efforts From Diagnostics To Cardiac Therapeutics

EU Group Makes Progress In Alliance For Rare Diseases

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 17, 2025.
Medline raises $6.3B in fourth med-tech IPO of December
BioWorld MedTech
Medline Inc. returned to the public markets with a blockbuster IPO of $6.26 billion, reportedly this year’s largest IPO globally. The upsized offering of more...
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 17, 2025.
Vitesse finesse pays off: DBV wins in peanut allergy phase III
BioWorld
DBV Technologies SA’s pivotal phase III trial with the Viaskin Peanut allergy patch came through for the company, and officials plan a BLA filing with the U.S....
Acryl raises $28M IPO, aiming to bridge medical divide with AI
BioWorld MedTech
Acryl Inc. debuted on South Korea’s Kosdaq Dec. 16, raising ₩42.12 billion ($28.5 million) in an IPO. Shares (KOSDAQ:0007C0) closed at ₩67,000 on the first day,...